Medisus Pharma

The Ribaxa 150 mg tablet manufactured by Dr. Reddy's Laboratories Ltd. is a prescription anticancer medication containing olaparib. It is used for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers, particularly in patients with specific genetic mutations (like BRCA). 

Olpaza 150 mg is a prescription anti-cancer medication containing Olaparib, which is a targeted therapy known as a PARP inhibitor. It is primarily used to treat certain types of ovarian, breast, pancreatic, and prostate cancers. 

Olpaza 100 (Olaparib) is a targeted anti-cancer drug, a PARP inhibitor, used for pancreatic, prostate, breast, and ovarian cancers, working by blocking cancer cells' DNA repair mechanisms (PARP), leading to cell death; it's taken as a tablet, alone or with other chemo, and requires monitoring for side effects like fatigue, nausea, and blood count changes.

Olzapar 150 is a targeted anti-cancer drug containing Olaparib, a PARP inhibitor, used for cancers like ovarian, breast, pancreatic, and prostate, working by blocking DNA repair in cancer cells, causing them to die, and requires doctor supervision due to potential side effects like fatigue, nausea, and blood count changes, with strict contraception needed. 

The IBYRA 150 tablet is a prescription anti-cancer medication containing Olaparib, which belongs to a class of drugs known as PARP inhibitors. It is used to treat specific types of ovarian, breast, pancreatic, and prostate cancers. 

Olzapar 100 mg tablets contain the active ingredient Olaparib, an anti-cancer medication classified as a PARP inhibitor. It is a targeted therapy primarily used to treat certain types of ovarian, breast, pancreatic, and prostate cancers, particularly in patients with specific genetic mutations (like BRCA).